NSCLC

[Scientific Reports] Researchers found heightened expression of RB-family (RBL) 2 and reduced expression of AURKA/B pathway genes was associated with improved outcomes in p53 wild-type but not p53 mutant NSCLC patients.

[Current Oncology Reports] The authors review the current role for CTLA-4 inhibitors in early-stage resectable NSCLC, unresectable stage III NSCLC, and in metastatic NSCLC.

[Turning Point Therapeutics] Turning Point Therapeutics, Inc. announced that the company has received clearance from the FDA for the company’s Investigational New Drug application for the combination of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer.

[Scientific Reports] Secretion analysis revealed that cancer cells vary in their secretion level, with some cell lines having relatively low secretion rates.

[Cell Death & Disease] Researchers explored the downstream mechanism of Jumonji domain containing protein 2C (JMJD2C) in NSCLC from the long non-coding RNA metastasis associated with lung adenocarcinoma transcript 1/microRNA-503-5p/septin 2 axis.

[Amgen, Inc.] Amgen announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer that has progressed after systemic anticancer therapy.